|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk for colorectal cancer in ulcerative colitis:Changes,causes and management strategies显示文摘The risk of colorectal cancer for any patient with ulcer-ative colitis is known to be elevated, and is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. Risk factors for cancer in-clude extent and duration of ulcerative colitis, primary sclerosing cholangitis, a family history of sporadic colorectal cancer, severity of histologic bowel inflam-mation, and in some studies, young age at onset of colitis. In this review, the authors discuss recent epide-miological trends and causes for the observed chang-es. Population-based studies published within the past 5 years suggest that this risk has decreased over time, despite the low frequency of colectomies. The crude annual incidence rate of colorectal cancer in ulcerative colitis ranges from approximately 0.06% to 0.16% with a relative risk of 1.0-2.75. The exact mechanism for this change is unknown; it may partly be explained by the more widespread use of maintenance therapy and surveillance colonoscopy. | Peter Laszlo Lakatos Laszlo Lakatos | 2008 | World Journal of Gastroenterology2008，14，25： | 56 |
| 2 | 炎症性肠病诊断与治疗的共识意见(2012年·广州)溃疡性结肠炎治疗部分解读显示文摘溃疡性结肠炎(UC)是一种病因尚不十分清楚的慢性非特异性肠道炎症性疾病,近十余年来国内就诊人数呈逐步增加趋势。2012年,中华医学会消化病学分会炎症性肠病(IBD)学组对2007年版中国IBD诊治共识进行了修订。本文以本次共识意见为基础,解读共识意见中建议的精髓,剖析UC治疗中需注意的要点,分层阐述氨基水杨酸制剂、糖皮质激素、免疫抑制剂、生物制剂在UC治疗中的新进展,以期提高临床医师对UC治疗的认知水平。 | 杨红 钱家鸣 | 2012 | 胃肠病学2012，17，12： | 31 |
| 3 | 骨髓间充质干细胞移植治疗炎症性肠病小鼠结肠炎的有效性及肿瘤学安全性显示文摘背景:骨髓间充质干细胞输注有望成为临床治疗炎症性肠病的新的有效生物治疗手段,但其肿瘤学安全性问题令人担忧,是决定间充质干细胞能否广泛用于炎症性肠病治疗的关键,亟待研究。目的:利用小鼠模型观察骨髓间充质干细胞输注对炎症性肠病结肠炎的疗效,并明确间充质干细胞对炎症性肠病炎症癌变的影响。方法:应用葡聚糖硫酸钠构建Balb/c(H-2d)小鼠的实验性结肠炎模型,经尾静脉输注分离培养的同系基因型骨髓间充质干细胞,对比观察间充质干细胞的疗效并评价结肠炎的组织病理学改善情况;应用葡聚糖硫酸钠联合偶氮氧甲烷构建Balb/c(H-2d)小鼠的结肠炎癌变模型,对比观察间充质干细胞输注后小鼠肠道肿瘤的形成情况。结果与结论:在葡聚糖硫酸钠结肠炎模型,骨髓间充质干细胞组在实验结束时体质量丧失、大便潜血较PBS组均有减轻;间充质干细胞组中结肠组织炎症损伤严重度评分更低,镜下小鼠远端结肠黏膜结构基本完整,有小范围上皮缺损或隐窝缺损,黏膜层和黏膜下层较多炎症细胞浸润,可见毛细血管和小血管增生;体内示踪可见输注的间充质干细胞向结肠炎症病灶处黏膜下层归巢定殖。在葡聚糖硫酸钠/偶氮氧甲烷结肠炎癌变模型,间充质干细胞组小鼠肠道肿瘤数量及肿瘤负荷均明显小于对照组。结果提示输注骨髓间充质干细胞能明显改善炎症性肠病小鼠的结肠炎症病变,并抑制结肠炎向肿瘤的恶性转化,为间充质干细胞治疗炎症性肠病的生物安全性提供了客观的理论依据。 | 何小文 陈泽贤 张珑涓 何晓生 练磊 柯嘉 林绪涛 陈曦 吴小剑 兰平 | 2014 | 中国组织工程研究2014，18，23： | 8 |
| 4 | 重症溃疡性结肠炎119例临床和病理分析显示文摘目的对重症溃疡性结肠炎(UC)进行临床和病理分析并讨论其临床意义。方法重症溃疡性结肠炎患者119例,全部患者均符合2000年成都全国炎症性肠病会议修改的UC诊断标准,并经纤维结肠镜检查和X线钡灌肠检查,以及组织学检查确诊,连续粪培养2次排除细菌感染,同时排除阿米巴肠病、血吸虫病、肠道肿瘤和内分泌疾病。病变包括乙状结肠55例,降结肠31例,结肠脾曲20例和横结肠13例;临床类型包括初发型25例,慢性复发型54例和持续型40例。采取肠外静脉补充足够的营养,完全胃肠道休息,治疗4周后进行纤维肠镜检查。结果重症UC经过4周治疗后临床痊愈36例(30.3%),好转65例(54.6%),无效18例(15.1%),总有效率84.9%。初发型、复发型和持续型UC内镜下和组织学存在一定差异,但治疗总有效率无明显差异(P>0.05),分别为88.0%,87.0%和80.0%。全部患者血清AST、ALT在正常范围,血清白蛋白治疗后明显好转[g/L,(38.2±9.9)vs(22.4±8.8),P<0.01]。结论初发型、复发型和持续型UC内镜下和组织学存在一定差异,肠外静脉高营养疗法是一种有效可行的方法。 | 李陕区 郭学刚 许昌泰 | 2005 | 山西医科大学学报2005，36，6： | 3 |
| 5 | Indications for 5-aminosalicylate in inflammatory bowel disease:Is the body of evidence complete?显示文摘Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and con- comitant drug pharmacokinetics, or in chemoprevention against inflammatory bowel disease (IBD)-related co- lonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dos- age to improve compliance. Therefore, due to its supe- rior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, pae- diatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use. | Ad A van Bodegraven Chris JJ Mulder | 2006 | World Journal of Gastroenterology2006，12，38： | 2 |
| 6 | 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro显示文摘AIM: To investigate the effects of 5-aminosalicylic acid (5-ASA) in combination with nimesulide on the proliferation of HT-29 colon carcinoma cells and its potential mechanisms. METHODS: Inhibitory effects of drugs (5-ASA,nimesulide and their combination) on HT-29 colon carcinoma cells were investigated by thiazolyl blue tetrazolium bromide (MTT) assay. Cellular apoptosis and proliferation were detected by TUNEL assay and immunocytochemical staining,respectively. RESULTS: Pretreatment with 5-ASA or nimesulide at the concentration of 10-1000 μmol/L inhibited proliferation of HT-29 colon carcinoma cells in a dose-dependent manner in vitro (t = 5.122,P < 0.05; t = 3.086,P < 0.05,respectively). The inhibition rate of HT-29 colon carcinoma cell proliferation was also increased when pretreated with 5-ASA (100 μmol/L) or nimesulide (100 μmol/L) for 12-96 h,which showed an obvious time-effect relationship (t = 6.149,P < 0.05; t = 4.159,P < 0.05,respectively). At the concentration of 10-500 μmol/L,the apoptotic rate of HT-29 colon carcinoma cells significantly increased (t = 18.156,P < 0.001; t = 19.983,P < 0.001,respectively),while expression of proliferating cell nuclear antigen (PCNA) was remarkably decreased (t = 6.828,P < 0.05; t = 14.024,P < 0.05,respectively). 5-ASA in combination with nimesulide suppressed the proliferation of HT-29 colon carcinoma cells more than either of these agents in a dose-dependent and time-dependent manner (t = 5.448,P < 0.05; t = 4.428,P < 0.05,respectively). CONCLUSION: 5-ASA and nimesulide may inhibit the proliferation of HT-29 colon carcinoma cells and coadministration of these agents may have additional chemopreventive potential. | Hai-Ming Fang Qiao Mei Jian-Ming Xu Wei-Juan Ma | 2007 | World Journal of Gastroenterology2007，13，20： | 2 |
| 7 | 溃疡性结肠炎药物治疗现状显示文摘溃疡性结肠炎是一种慢性、反复发作的大肠疾病,病变可以累及整个结肠(全结肠炎),或又累及直肠(溃疡性直肠炎),或两者兼有。溃疡性结肠炎的病因可能与免疫因素、遗传因素和环境因素有关。对溃疡性结肠炎的治疗主要有激素、磺胺类和免疫抑制等。本文综述溃疡性结肠炎药物治疗现状。 | 许昌泰 郭学刚 | 2005 | 世界感染杂志2005，5，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员